Chester County News and Community Website
BERWYN, PA — Recent developments have been flourishing for Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX). The Pennsylvania-based pharmaceutical innovator recently unveiled its financial records for 2023 and shared a series of …
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions Read More
NEWTOWN, PA — In a market landscape dominated by titans in the biotech and healthcare technology sectors, Helius Medical Technologies, Inc. (Nasdaq: HSDT) found themselves in a David versus Goliath …
Helius Medical Technologies: Strides Towards Reimbursement for Innovative PoNS Therapy Amidst Financial Challenges Read More
NEWTOWN SQUARE, PA — In recent developments from the pharmaceutical industry, ArriVent BioPharma Inc. (Nasdaq: AVBP), a notable player in the arena of breakthrough cancer therapy, has seen a transformative …
ArriVent BioPharma Unveils Promising Developments and Strong Financial Performance in 2023 Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a key player in the pharmaceutical industry, recently unveiled its financial results for the fourth quarter and full year of 2023, which …
Galera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challenges Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has recently shared its financial results for the full year of 2023, accompanying these figures with a business update for …
Orchestra BioMed: Continuing the Momentum into a Promising Future Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) recently made public its financial results for 2023’s fourth quarter and the entire year.
STRATA Skin Sciences Unveils 2023 Financial Results: A Look into an Evolving Business Model Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently announced financial results for the fourth quarter and full year ended December 31, 2023. The company also provided an update on …
FDA Clearance Paves Way for Aprea Therapeutics’ Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) recently revealed its financial performance for both the fourth quarter and the full calendar year ending on December 31, 2023. A cumulative …
TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024 Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company specializing in the development of treatments for solid tumors and gynecological cancers, has unveiled its financial outcomes for the …
Context Therapeutics Adjusts Strategy and Reports Financial Update Amidst R&D Pivot Read More
PHILADELPHIA, PA — The biotech company Cabaletta Bio, Inc. (Nasdaq: CABA), known for its pioneering work in autoimmune disease therapeutics, recently announced its financial results and business updates for the …
Cabaletta Bio Forges Ahead: A Strong Year Lays Groundwork for Groundbreaking Autoimmune Disease Therapies Read More